10-Q Filing

ARROWHEAD PHARMACEUTICALS, INC. CIK: 879407 Q1 2024

Filing Information

Form Type	10-Q
Accession Number	`0001628280-24-003492`
Period End Date	20231231
Filing Date	20240206
Fiscal Year	2024
Fiscal Period	Q1
XBRL Instance	arwr-20231231_htm.xml

Filing Contents

This filing contains the following financial statements:

Balance Sheet 70 Income Statement 42 Cash Flow Statement 58 Stockholders Equity 20

Balance Sheet 70 line items

Line Item	Tag	Value	Unit	Period
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, par value (in dollars per share)	`CommonStockParOrStatedValuePerShare`	$0.00	USD	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	290.00M	shares	Point-in-time
Common stock, shares authorized (in shares)	`CommonStockSharesAuthorized`	290.00M	shares	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$202.25M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$58.22M	USD	Point-in-time
Cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	107.31M	shares	Point-in-time
Common stock, shares issued (in shares)	`CommonStockSharesIssued`	107.50M	shares	Point-in-time
Available-for-sale securities, at fair value	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$162.06M	USD	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	107.50M	shares	Point-in-time
Common stock, shares outstanding (in shares)	`CommonStockSharesOutstanding`	107.31M	shares	Point-in-time
Available-for-sale securities, at fair value	`AvailableForSaleSecuritiesDebtSecuritiesCurrent`	$292.74M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$10.52M	USD	Point-in-time
Prepaid expenses	`PrepaidExpenseCurrent`	$8.81M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.10M	USD	Point-in-time
Other current assets	`OtherAssetsCurrent`	$7.08M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$237.90M	USD	Point-in-time
Total current assets	`AssetsCurrent`	$419.52M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$290.26M	USD	Point-in-time
Property, plant and equipment, net	`PropertyPlantAndEquipmentNet`	$333.41M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$10.26M	USD	Point-in-time
Intangible assets, net	`FiniteLivedIntangibleAssetsNet`	$9.84M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$44.91M	USD	Point-in-time
Right-of-use assets	`OperatingLeaseRightOfUseAsset`	$45.30M	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$232.00K	USD	Point-in-time
Other assets	`OtherAssetsNoncurrent`	$210.00K	USD	Point-in-time
Total Assets	`Assets`	$626.29M	USD	Point-in-time
Total Assets	`Assets`	$765.55M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$35.87M	USD	Point-in-time
Accounts payable	`AccountsPayableCurrent`	$4.46M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$46.60M	USD	Point-in-time
Accrued expenses	`AccruedLiabilitiesCurrent`	$39.76M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$17.96M	USD	Point-in-time
Accrued payroll and benefits	`EmployeeRelatedLiabilitiesCurrent`	$8.78M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$10.56M	USD	Point-in-time
Lease liabilities	`OperatingLeaseLiabilityCurrent`	$3.42M	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	-	USD	Point-in-time
Deferred revenue	`ContractWithCustomerLiabilityCurrent`	$866.00K	USD	Point-in-time
Other liabilities	`OtherLiabilitiesCurrent`	$435.00K	USD	Point-in-time
Other liabilities	`OtherLiabilitiesCurrent`	$461.00K	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$63.72M	USD	Point-in-time
Total current liabilities	`LiabilitiesCurrent`	$105.46M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$115.16M	USD	Point-in-time
Lease liabilities, net of current portion	`OperatingLeaseLiabilityNoncurrent`	$104.61M	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	$268.33M	USD	Point-in-time
Liability related to the sale of future royalties	`RoyaltiesLiabilityNoncurrent`	$273.69M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$372.93M	USD	Point-in-time
Total long-term liabilities	`LiabilitiesNoncurrent`	$388.85M	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Commitments and contingencies (Note 7)	`CommitmentsAndContingencies`	-	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,500 and 107,312 shares	`CommonStockValue`	$200.00K	USD	Point-in-time
Common stock, $0.001 par value: Authorized 290,000 shares; issued and outstanding 107,500 and 107,312 shares	`CommonStockValue`	$200.00K	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.32B	USD	Point-in-time
Additional paid-in capital	`AdditionalPaidInCapitalCommonStock`	$1.30B	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-3.22M	USD	Point-in-time
Accumulated other comprehensive loss	`AccumulatedOtherComprehensiveIncomeLossNetOfTax`	$-1.25M	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.03B	USD	Point-in-time
Accumulated deficit	`RetainedEarningsAccumulatedDeficit`	$-1.16B	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders equity	`StockholdersEquity`	$271.34M	USD	Point-in-time
Total Arrowhead Pharmaceuticals, Inc. stockholders equity	`StockholdersEquity`	$160.41M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$15.82M	USD	Point-in-time
Noncontrolling interest	`MinorityInterest`	$13.31M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$173.71M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Total noncontrolling interest and stockholders equity	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$765.55M	USD	Point-in-time
Total Liabilities, Noncontrolling Interest and Stockholders Equity	`LiabilitiesAndStockholdersEquity`	$626.29M	USD	Point-in-time

Income Statement 42 line items

Line Item	Tag	Value	Unit	Period
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$62.55M	USD	1 Quarter
Revenue	`RevenueFromContractWithCustomerExcludingAssessedTax`	$3.55M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$83.69M	USD	1 Quarter
Research and development	`ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost`	$116.49M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$23.61M	USD	1 Quarter
General and administrative	`GeneralAndAdministrativeExpense`	$20.98M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$104.68M	USD	1 Quarter
Total operating expenses	`OperatingExpenses`	$140.10M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-136.54M	USD	1 Quarter
Operating loss	`OperatingIncomeLoss`	$-42.13M	USD	1 Quarter
Interest income	`InvestmentIncomeInterestAndDividend`	$2.68M	USD	1 Quarter
Interest income	`InvestmentIncomeInterestAndDividend`	$2.80M	USD	1 Quarter
Interest expense	`InterestExpense`	$5.37M	USD	1 Quarter
Interest expense	`InterestExpense`	$2.85M	USD	1 Quarter
Other, net	`OtherNonoperatingIncomeExpense`	$507.00K	USD	1 Quarter
Other, net	`OtherNonoperatingIncomeExpense`	$421.00K	USD	1 Quarter
Total other (expense) income	`NonoperatingIncomeExpense`	$340.00K	USD	1 Quarter
Total other (expense) income	`NonoperatingIncomeExpense`	$-2.14M	USD	1 Quarter
Loss before income tax (benefit) expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-41.79M	USD	1 Quarter
Loss before income tax (benefit) expense and noncontrolling interest	`IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest`	$-138.69M	USD	1 Quarter
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$-3.31M	USD	1 Quarter
Income tax (benefit) expense	`IncomeTaxExpenseBenefit`	$17.00K	USD	1 Quarter
Net loss including noncontrolling interest	`ProfitLoss`	$-41.81M	USD	1 Quarter
Net loss including noncontrolling interest	`ProfitLoss`	$-135.38M	USD	1 Quarter
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-2.51M	USD	1 Quarter
Net loss attributable to noncontrolling interest, net of tax	`NetIncomeLossAttributableToNoncontrollingInterest`	$-486.00K	USD	1 Quarter
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-41.33M	USD	1 Quarter
Net loss attributable to Arrowhead Pharmaceuticals, Inc.	`NetIncomeLoss`	$-132.86M	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$-1.24	USD	1 Quarter
Basic (in dollars per share)	`EarningsPerShareBasic`	$-0.39	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-1.24	USD	1 Quarter
Diluted (in dollars per share)	`EarningsPerShareDiluted`	$-0.39	USD	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	107.42M	shares	1 Quarter
Basic (in shares)	`WeightedAverageNumberOfSharesOutstandingBasic`	106.04M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	106.04M	shares	1 Quarter
Diluted (in shares)	`WeightedAverageNumberOfDilutedSharesOutstanding`	107.42M	shares	1 Quarter
Change in unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	1 Quarter
Change in unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$1.91M	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$58.00K	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-133.41M	USD	1 Quarter
Comprehensive loss	`ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest`	$-41.93M	USD	1 Quarter

Cash Flow Statement 58 line items

Line Item	Tag	Value	Unit	Period
Net loss	`ProfitLoss`	$-41.81M	USD	1 Quarter
Net loss	`ProfitLoss`	$-135.38M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$19.39M	USD	1 Quarter
Stock-based compensation	`ShareBasedCompensation`	$19.69M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$4.26M	USD	1 Quarter
Depreciation and amortization	`DepreciationAndAmortization`	$2.69M	USD	1 Quarter
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$835.00K	USD	1 Quarter
(Accretion) amortization of note premiums/discounts	`InvestmentIncomeNetAmortizationOfDiscountAndPremium`	$-690.00K	USD	1 Quarter
Realized gain on investments	`RealizedInvestmentGainsLosses`	$80.00K	USD	1 Quarter
Realized gain on investments	`RealizedInvestmentGainsLosses`	-	USD	1 Quarter
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	$5.37M	USD	1 Quarter
Non-cash interest expense on liability related to the sale of future royalties	`NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties`	$2.85M	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	-	USD	1 Quarter
Accounts receivable	`IncreaseDecreaseInAccountsReceivable`	$38.16M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$-10.53M	USD	1 Quarter
Prepaid expenses and other current assets	`IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets`	$1.75M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-2.07M	USD	1 Quarter
Accounts payable	`IncreaseDecreaseInAccountsPayable`	$-12.46M	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$-7.20M	USD	1 Quarter
Accrued expenses	`IncreaseDecreaseInAccruedLiabilities`	$408.00K	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-22.98M	USD	1 Quarter
Deferred revenue	`IncreaseDecreaseInContractWithCustomerLiability`	$-866.00K	USD	1 Quarter
Operating lease, net	`IncreaseDecreaseInOperatingLeaseLiability`	$559.00K	USD	1 Quarter
Operating lease, net	`IncreaseDecreaseInOperatingLeaseLiability`	$3.80M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-117.84M	USD	1 Quarter
Net cash used in operating activities	`NetCashProvidedByUsedInOperatingActivities`	$-75.52M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$68.66M	USD	1 Quarter
Purchases of property and equipment	`PaymentsToAcquirePropertyPlantAndEquipment`	$38.91M	USD	1 Quarter
Purchases of investments	`PaymentsToAcquireInvestments`	-	USD	1 Quarter
Purchases of investments	`PaymentsToAcquireInvestments`	$111.20M	USD	1 Quarter
Proceeds from sales and maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$69.42M	USD	1 Quarter
Proceeds from sales and maturities of investments	`ProceedsFromSaleMaturityAndCollectionsOfInvestments`	$133.50M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$-80.69M	USD	1 Quarter
Net cash provided by (used in) investing activities	`NetCashProvidedByUsedInInvestingActivities`	$64.84M	USD	1 Quarter
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$576.00K	USD	1 Quarter
Proceeds from the exercises of stock options	`ProceedsFromStockOptionsExercised`	$267.00K	USD	1 Quarter
Proceeds from the sale of future royalties	`ProceedsFromSaleOfFutureRoyalties`	-	USD	1 Quarter
Proceeds from the sale of future royalties	`ProceedsFromSaleOfFutureRoyalties`	$250.00M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$250.58M	USD	1 Quarter
Net cash provided by financing activities	`NetCashProvidedByUsedInFinancingActivities`	$267.00K	USD	1 Quarter
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$-52.73M	USD	1 Quarter
Net (decrease) increase in cash, cash equivalents and restricted cash	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect`	$94.37M	USD	1 Quarter
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$58.00K	USD	1 Quarter
Effect of exchange rate on cash, cash equivalents and restricted cash	`EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$-122.00K	USD	1 Quarter
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$202.25M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$58.22M	USD	Point-in-time
BEGINNING OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$202.25M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$110.89M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$58.22M	USD	Point-in-time
END OF PERIOD	`CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents`	$108.00M	USD	Point-in-time
Interest paid	`InterestPaidNet`	-	USD	1 Quarter
Interest paid	`InterestPaidNet`	-	USD	1 Quarter
Income taxes (paid) refunded	`IncomeTaxesPaidNet`	-	USD	1 Quarter
Income taxes (paid) refunded	`IncomeTaxesPaidNet`	$-999.00K	USD	1 Quarter
Capital expenditures included in accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$14.04M	USD	1 Quarter
Capital expenditures included in accrued expenses	`CapitalExpendituresIncurredButNotYetPaid`	$11.29M	USD	1 Quarter

Stockholders Equity 20 line items

Line Item	Tag	Value	Unit	Period
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$173.71M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Beginning balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$19.39M	USD	1 Quarter
Stock-based compensation	`AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue`	$19.69M	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$576.00K	USD	1 Quarter
Exercise of stock options	`StockIssuedDuringPeriodValueStockOptionsExercised`	$267.00K	USD	1 Quarter
Exercise of stock options (in shares)	`StockIssuedDuringPeriodSharesStockOptionsExercised`	33,825.00	shares	1 Quarter
Common stock - restricted stock units vesting	`StockIssuedDuringPeriodValueRestrictedStockAwardGross`	-	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$-122.00K	USD	1 Quarter
Foreign currency translation adjustments	`OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax`	$58.00K	USD	1 Quarter
Change in unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	-	USD	1 Quarter
Change in unrealized losses on available-for-sale securities	`OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax`	$1.91M	USD	1 Quarter
Net loss	`ProfitLoss`	$-41.81M	USD	1 Quarter
Net loss	`ProfitLoss`	$-135.38M	USD	1 Quarter
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$173.71M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$418.34M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$287.16M	USD	Point-in-time
Ending balance	`StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest`	$396.37M	USD	Point-in-time

Data is extracted from SEC EDGAR XBRL filings. Values shown are as reported in the filing.